Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915224 | 0.86 | GNAI3 (0.44) | DRD2SIGMAR1HSD17B10HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL29165064 | 0.85 | GNAI3 (0.47) | DRD2SIGMAR1HSD17B10HTR2AHTR2C | |
| SCHEMBL4901796 | 0.85 | GNAI3 (0.52) | HSD17B10GAAGNAI3GNAO1GNAI1 | |
| SCHEMBL21084328 | 0.83 | GNAI3 (0.55) | GAAGNAI3GNAO1GNAI1 | |
| SCHEMBL4914105 | 0.83 | GNAI3 (0.55) | GAAGNAI3GNAO1GNAI1 | |
| SCHEMBL13632361 | 0.81 | HSD17B10 (0.46) | DRD2HSD17B10GNAI3GNAO1GNAI1 | |
| SCHEMBL9534288 | 0.81 | HSD17B10 (0.38) | HSD17B10HRH3GAAGNAI3GNAO1 | |
| SCHEMBL553965 | 0.80 | HSD17B10 (0.47) | HSD17B10NPC1RAB9APOLBGAA | |
| SCHEMBL5574053 | 0.80 | HSD17B10 (0.47) | SIGMAR1HSD17B10HRH3 | |
| SCHEMBL31298001 | 0.80 | SIGMAR1 (0.38) | DRD2SIGMAR1HSD17B10HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300145-B | Tri-aromatic ring compound targeting STAT3 bifunctional phosphorylation site and application thereof | 上海宇耀生物科技有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-112300145-A | Three-aromatic ring compound targeting STAT3 bifunctional phosphorylation site and application thereof | 上海宇耀生物科技有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-111954532-A | Anti-tumor multi-drug resistance of heteroaryl amide compounds, application of heteroaryl amide compounds in treating cancer and protein-drug molecular compound | 上海交通大学医学院附属瑞金医院 | 2020-11-17 | — | — | CN | claimed |
| CN-111295387-A | Heteroaryl amide compound, preparation method thereof, medicinal composition and application thereof | 上海交通大学医学院附属瑞金医院 | 2020-06-16 | — | — | CN | claimed |
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | claimed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4423090-A2 | ANTAGONISTS OF GPR39 PROTEIN | Vasocardea, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-112300145-B | Tri-aromatic ring compound targeting STAT3 bifunctional phosphorylation site and application thereof | 上海宇耀生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-115996908-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143163-A1 | ANTAGONISTS OF GPR39 PROTEIN | Oregon Health & Science University (US) | 2023-03-08 | — | — | EP | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
| EP-0277836-B1 | THIAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-06-02 | — | — | EP | disclosed |
| US-5104888-A | Anticholesterol or antidiabetic agents | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| US-4873255-A | REDUCE BLOOD GLUCOSE AND BLOOD LIPID LEVELS | SANKYO COMPANY LIMITED (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0277836-A1 | Thiazolidinone derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-08-10 | — | — | EP | disclosed |
| EP-0207581-A2 | Thiazolidine derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |